[go: up one dir, main page]

BR9510175A - Inibidores contendo ácido hidroxâmico de metaloproteases de matriz - Google Patents

Inibidores contendo ácido hidroxâmico de metaloproteases de matriz

Info

Publication number
BR9510175A
BR9510175A BR9510175A BR9510175A BR9510175A BR 9510175 A BR9510175 A BR 9510175A BR 9510175 A BR9510175 A BR 9510175A BR 9510175 A BR9510175 A BR 9510175A BR 9510175 A BR9510175 A BR 9510175A
Authority
BR
Brazil
Prior art keywords
hydroxamic acid
matrix metalloproteases
inhibitors containing
containing hydroxamic
inhibitors
Prior art date
Application number
BR9510175A
Other languages
English (en)
Inventor
Kenneth Edward Yelm
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9510175A publication Critical patent/BR9510175A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9510175A 1994-12-29 1995-12-13 Inibidores contendo ácido hidroxâmico de metaloproteases de matriz BR9510175A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/366,062 US5639746A (en) 1994-12-29 1994-12-29 Hydroxamic acid-containing inhibitors of matrix metalloproteases
PCT/US1995/016140 WO1996020918A1 (en) 1994-12-29 1995-12-13 Hydroxamic acid-containing inhibitors of matrix metalloproteases

Publications (1)

Publication Number Publication Date
BR9510175A true BR9510175A (pt) 1997-10-14

Family

ID=23441517

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9510175A BR9510175A (pt) 1994-12-29 1995-12-13 Inibidores contendo ácido hidroxâmico de metaloproteases de matriz

Country Status (11)

Country Link
US (1) US5639746A (pt)
EP (1) EP0800510A1 (pt)
JP (1) JPH10512241A (pt)
KR (1) KR980700963A (pt)
CN (1) CN1171780A (pt)
AU (1) AU706409B2 (pt)
BR (1) BR9510175A (pt)
CA (1) CA2208679A1 (pt)
NO (1) NO973035L (pt)
NZ (1) NZ298677A (pt)
WO (1) WO1996020918A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199900400T2 (xx) * 1996-08-28 1999-05-21 The Procter & Gamble Company Heterosiklik metaloproteaz inhibit�rleri.
WO1998015525A1 (en) * 1996-10-07 1998-04-16 Sumitomo Pharmaceuticals Co., Ltd. Hydroxamic acids
US20030206874A1 (en) * 1996-11-21 2003-11-06 The Proctor & Gamble Company Promoting whole body health
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6569636B2 (en) * 1998-05-29 2003-05-27 Hawaii Biotechnology Group, Inc. Assay for modulators of metallo-enzyme activity
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
CA2347671A1 (en) 1998-12-24 2000-07-06 Dupont Pharmaceuticals Company Succinoylamino benzodiazepines as inhibitors of a.beta. protein production
EP1165500A1 (en) 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
AU7997700A (en) 1999-10-08 2001-04-23 Du Pont Pharmaceuticals Company Amino lactam sulfonamides as inhibitors of abeta protein production
JP2003523345A (ja) 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
US6713476B2 (en) 2000-04-03 2004-03-30 Dupont Pharmaceuticals Company Substituted cycloalkyls as inhibitors of a beta protein production
CA2404023A1 (en) * 2000-04-03 2001-10-11 Richard E. Olson Cyclic lactams as inhibitors of a.beta. protein production
JP2004500419A (ja) 2000-04-11 2004-01-08 デュポン　ファーマシューティカルズ　カンパニー Ａβタンパク質産生阻害剤としての置換ラクタム
HK1049333A1 (zh) 2000-06-01 2003-05-09 Bristol-Myers Squibb Pharma Company 以环状琥珀酸酯代替内酰胺，作为制造Aβ蛋白质的抑制剂
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
DE60134854D1 (de) * 2000-06-30 2008-08-28 Procter & Gamble Orale zubereitungen, die wirtsantwortmodulierenden wirkstoffe enthalten
MXPA03000041A (es) * 2000-06-30 2003-10-15 Procter & Gamble Composiciones orales que comprenden agentes microbianos.
AU2003237224A1 (en) * 2002-05-29 2003-12-19 Merck And Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
CN103965128B (zh) * 2008-01-08 2018-04-03 兰休斯医疗成像公司 作为显像剂的n‑烷氧基酰胺共轭物
US8877157B2 (en) 2009-07-08 2014-11-04 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
RU2746850C2 (ru) * 2016-04-18 2021-04-21 Виворион Терапьютикс Аг Новые ингибиторы меприна альфа и бета

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
US4771038A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
AU608759B2 (en) * 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
IT1224627B (it) * 1988-04-12 1990-10-04 Guidotti & C Spa Labor Ammidi di acidi ciclometilen_1,2_dicarbossilici adattivita' terapeutica, procedimenti per la loro preparazione e composizioni farmaceutiche che le contengono.
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
WO1991008737A2 (en) * 1989-12-16 1991-06-27 Fisons Plc Pharmacologically active amide carboxylate derivatives
JPH04217950A (ja) * 1990-03-28 1992-08-07 Asahi Chem Ind Co Ltd ヒドロキサム酸誘導体および酵素阻害剤ならびに抗潰瘍剤
DE4011172A1 (de) * 1990-04-06 1991-10-10 Degussa Verbindungen zur bekaempfung von pflanzenkrankheiten
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
US5202321A (en) * 1991-06-13 1993-04-13 Merck Frosst Canada, Inc. Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis
IL98681A (en) * 1991-06-30 1997-06-10 Yeda Rehovot And Dev Company L Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives
DE4127842A1 (de) * 1991-08-22 1993-02-25 Rhone Poulenc Rorer Gmbh 5-((omega)-arylalky)-2-thienyl alkansaeuren, ihre salze und/oder ihre derivate
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
IT1252708B (it) * 1991-12-23 1995-06-26 Guidotti & C Spa Labor Sali stabili dell'acido (+)-(1r,2s)-2((n-(2-idrossilammino-2-ossoetil)-n-metilammino)carbonil)cicloesan-1-carbossilico,ad attivita' ace inibitrice, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
JP3348725B2 (ja) * 1992-04-07 2002-11-20 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤
EP1002556A3 (en) * 1992-05-01 2001-01-10 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
IT1264860B1 (it) * 1993-06-21 1996-10-17 Guidotti & C Spa Labor Derivati di acidi cis- e trans-2(((2-(isdrossiammino)-2-ossoetil)- alchilammino)carbonil)cicloesancarbossilici

Also Published As

Publication number Publication date
NO973035L (no) 1997-08-29
CN1171780A (zh) 1998-01-28
MX9704968A (es) 1997-10-31
WO1996020918A1 (en) 1996-07-11
KR980700963A (ko) 1998-04-30
AU706409B2 (en) 1999-06-17
NO973035D0 (no) 1997-06-27
NZ298677A (en) 1999-03-29
CA2208679A1 (en) 1996-07-11
EP0800510A1 (en) 1997-10-15
JPH10512241A (ja) 1998-11-24
AU4422096A (en) 1996-07-24
US5639746A (en) 1997-06-17

Similar Documents

Publication Publication Date Title
BR9510175A (pt) Inibidores contendo ácido hidroxâmico de metaloproteases de matriz
FI965156L (fi) Aryylisulfonamido-substituoidut hydroksaamihapot matriisimetalloproteinaasi-inhibiittoreina
NZ304689A (en) Lactam-containing hydroxamic acid derivatives and use as matrix metalloprotease (mmp) inhibitors
NO990184D0 (no) Fosfintbaserte inhibitorer for mtriks-metalloproteaser
BR9509802A (pt) Inibidores de metaloproteases de matriz
FI950262A7 (fi) Hydroksaamihappojohdokset metalloproteinaasi-inhibiittoreina
ATE226590T1 (de) Phosphinsäureamide als matrix metalloprotease inhibitoren
ATE257151T1 (de) Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren
ZA979233B (en) The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
IL129148A0 (en) The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
FI954351A7 (fi) Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina
ATE219058T1 (de) Alpha-substituierte arylsulphonamidohydroxamsaüre als tnf-alpha und matrix-metalloproteinase- inhibitoren
HUP9902083A3 (en) Sulfonamide inhibitors of matrix metalloproteinases
FI941766L (fi) sPLA2:n 1H-indoli-3-etikkahappohydratsidi-inhibiittoreita
EE9800187A (et) Trombiini inhibiitorite eelravimid
FI965019A7 (fi) Entsyymi-inhibiittoreita
DK96791D0 (da) Hydroxamsyrebaserede collagenaseinhibitorer
FI961857A7 (fi) Matriksin metalloproteaasien inhibiittorit
IL129149A0 (en) Beta-sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
GB9401129D0 (en) Hydroxamic acid derivatives as metalloproteinase inhibitors
FI960482A7 (fi) Matriksin metalloproteaasien inhibiittorit
EE03745B1 (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
FI960425L (fi) Fenyylisykloheksyylikarboksyylihappoamidien käyttö
GB9502858D0 (en) Novel use of matrix metalloproteinase inhibitors
GB9708133D0 (en) Novel use of matrix metalloproteinase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]